Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedPal AILSE:MPAL Debt-to-EBITDA is -0.11 as of Feb. 2026. The stock has 1 warning sign investors should review. Among 476 Healthcare Providers & Services companies, MedPal AI ranks worse than 210083.82% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for MedPal AI's Debt-to-EBITDA or its related term are showing as below:
LSE:MPAL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69 Med: -0.6 Max: -0.14
Current: -0.14
During the past 4 years, the highest Debt-to-EBITDA Ratio of MedPal AI was -0.14. The lowest was -0.69. And the median was -0.60.
LSE:MPAL's Debt-to-EBITDA is ranked worse than 100% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.21
vs LSE:MPAL: -0.14
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MedPal AI Debt-to-EBITDA Related Terms
MedPal AI Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for MedPal AI's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:MPAL vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, MedPal AI's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedPal AI Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedPal AI's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedPal AI's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Feb. 2026) EBITDA data.
MedPal AI (LSE:MPAL) has a Debt-to-EBITDA of -0.11 as of Feb. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MedPal AI. According to the industry distribution chart, MedPal AI ranks #999999 out of 476 companies in the Healthcare Providers & Services industry.
Is MedPal AI's Debt-to-EBITDA too high?
MedPal AI's current Debt-to-EBITDA is -0.11. Based on the distribution chart, MedPal AI ranks #999999 out of 476 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does MedPal AI's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedPal AI ranks #999999 out of 476 companies for Debt-to-EBITDA. This places MedPal AI in the lower half of its industry. The industry median Debt-to-EBITDA is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.21, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MedPal AI. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedPal AI's current Debt-to-EBITDA is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedPal AI stock overvalued right now?
MedPal AI (LSE:MPAL) has a current Debt-to-EBITDA of -0.11. The current Debt-to-EBITDA is -0.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MedPal AI (LSE:MPAL), the current Debt-to-EBITDA is -0.11 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MedPal AI PLC is a UK-based digital health and artificial intelligence company focused on the development and commercialisation of AI-enabled healthcare platforms.. Its platform aggregates data across devices and apps (including Apple Health, Fitbit, Garmin, and Google Fit) to deliver real-time, personalized health insights. The Company has two reportable segments, Software and Corporate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:MPAL has been successfully added to your 
